Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRAS TCR-Transduced PBL and Vaccine in Metastatic Solid Cancers
NCT06253520Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2024
- Primary completion
- Feb 2029
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-KRAS G12D mTCR PBL and SLATE-KRAS in metastatic cancer, sponsored by National Cancer Institute. Primary endpoints: Objective Response Rate at 20 weeks and Adverse Events at 4 weeks. Started May 2024; status: active, not recruiting.
02
Drugs
anti-KRAS G12D mTCR PBLSLATE-KRAS
03
Conditions
metastatic cancer
Beyond the preview
Go deeper on NCT06253520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06253520.